2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
May 2024 in “News Digital Object Group”
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
12 citations
,
February 2010 in “Tetrahedron Letters” New minoxidil compounds with better water solubility were made, but their full effects and safety need more research.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
8 citations
,
November 1978 in “British journal of dermatology/British journal of dermatology, Supplement” Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
November 2025 in “Journal of Investigative Dermatology” AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
2 citations
,
August 2025 in “Harm Reduction Journal” Non-medical steroid use in gym-goers is risky and needs better prevention and care strategies.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Truman Plus Male Enhancement is marketed as a natural testosterone booster to improve men's sexual health and energy.
September 2015 in “American journal of biomedicine” 4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly”
June 1982 in “Revista Colombiana de Obstetricia y Ginecología” El acetato de ciproterona trata problemas androgénicos como hirsutismo, acné, seborrea y alopecia con diferentes dosis y combinaciones.
January 2023 in “Reactions Weekly”
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.